Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer

Adenocarcinoma Clinical Trial

— PREPARE  

Official title:

A Randomized Phase II Trial of Preoperative Chemoradiation (Preop CRT) Followed by CapOx (Capecitabine Plus Oxaliplatin) Versus Preop CRT Alone for Locally Advanced Rectal Cancer (LARC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01952951
• Other study ID #: KCSG CO14-03
• Status: Active, not recruiting
• Phase: Phase 2
• First received: September 11, 2013
• Last updated: September 12, 2017
• Start date: June 2014
• Est. completion date: December 2019

Study information

• Verified date: September 2017
• Source: National Cancer Center, Korea
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current standard treatment of locally advanced rectal cancer (clinical stage II or III) is preoperative radiation with chemotherapy (CRT) followed by surgery. But this approach can be suboptimal for patients with high risk features (more deeply-seated tumor or many regional lymph nodes involved)that are associated with recurrence. This study test a hypothesis that CRT followed by chemotherapy before surgery can improve efficacy of preoperative treatment.

Description:

Downstaging rate with CRT using fluoropyrimidine monotherapy is usually 30-40%.In MRI-defined high-risk patients, downstaging rate with conventional fluoropyrimidine-based monotherapy with radiation has not been shown. We assume that the downstaging rate of chemoradiation arm (control arm) would be 30%, and that addition of CapOx after CRT (experimental arm) may increase downstaging rate 30% to 50%. A sample size of 52 patients per group is needed have 85% power to detect downstaging rate = 50% as compared to 30% with type I error rate of 15%. We will perform one interim futility analysis when half of the patients are recruited and evaluated for the primary endpoint. O'Brien-Fleming boundary will be considered. Therefore, when 26 patients per arm are evaluated, the interim futility analysis will be performed, and when the Z score at the interim is less than -0.09192 (one-sided p-value greater than 0.5366192), the study will be stopped for futility. Considering 5% follow-up loss, a sample size of 55 per arm (a total of 110 patients) will be studied.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 110
• Est. completion date: December 2019
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• histologically confirmed adenocarcinoma of the rectum

• distal margin of tumor located from 0 to 12 cm from anal verge measured by digital rectal examination

• high risk clinical stage II or III in MRI (satisfying at least one of the followings)

• circumferential resection margin < 1 mm involved

• low-lying tumor below anal verge 3 cm

• T3 > 5 mm extramural spread

• T4 (involving surrounding structures or peritoneum)

• cN2 (4 or more mixed signal intensity or irregularly bordered node or tumor deposit)

• age 20 years or more

• ECOG (Eastern Cooperative Oncology Group) performance status 0-2

• No prior chemotherapy, radiotherapy to pelvis

• Adequate bone marrow function

• Adequate renal function

• Adequate hepatic function

• patients must sign the informed consent indicating that they were aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria:

• malignant disease of the rectum other than adenocarcinoma or arisen from chronic inflammatory bowel disease

• any unresected synchronous colon cancer

• any distant metastases

• intestinal obstruction or impending obstruction, but decompressing colostomy is permitted

• any previous or concurrent malignancy withih 5 years other than non-melanoma skin cancer / in situ cancer of uterine cervix / early gastric cancer / thyroid cancer of low risk

• any other morbidity or situation with relative contraindication for chemoradiotherapy

• patients with history of significant gastric or small bowel resection, or malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that may compromise the absorption of capecitabine

• pregnant or lactating women or patients of childbearing potential not predicting adequate contraception

Related Conditions & MeSH terms

• Adenocarcinoma
• Rectal Neoplasms

Intervention

Drug:
• Capecitabine Oxaliplatin
after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.

Radiation:
• pelvic radiation capecitabine 5-fluorouracil
50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil

Locations

Country	Name	City	State
Korea, Republic of	Hallym University Sacred Heart Hospital	Anyang
Korea, Republic of	Gangneung Asan Hospital	Gangneung
Korea, Republic of	National Cancer Center	Goyang	Gyeonggi-do
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam	Gyeonggi-do
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Chung-Ang University Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
National Cancer Center, Korea	Korean Cancer Study Group

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	downstaging rate	downstaging rate is defined as the proportion of patients with ypStage (pathologic stage after preoperative treatment) 0 or I (from pathologic findings after preoperative treatment and surgery) out of all patients who were assigned to each arm.	expected average of 15 weeks after start of study treatment
Secondary	pathologic response	pathologic response is assessed by Dworak's grading system from postoperative specimen.	expected average of 15 weeks after start of study treatment
Secondary	radiologic response rate	radiologic response will be assessed according to RECIST (Response Evaluation Criteria in Solid Tumors) guideline 1.1	expected average of 14 weeks after start of study treatment
Secondary	toxicity profile	Toxicities or any adverse events during study treatment, surgery and follow-up period will be assessed according to NCI CTCAE (Common Terminology Criteria for Adverse Events) version 4.0	expected average of 35 weeks after start of study treatment
Secondary	pattern of failure	if any recurrent lesion is noticed, anatomic sites of recurrent lesions and the date and the name of exam or imaging study (physical exam, CT or MRI…) will be recorded in case report form.	3 years after surgery
Secondary	local control rate	Local recurrence is defined as tumor recurrence confined in radiation field (pelvic cavity). Cumulative incidence of local recurrence will be suggested.	3 years after surgery
Secondary	relapse-free survival	Time from date of operation to date of recurrence of disease or deaths due to recurrence or progression of disease.	3 years after surgery
Secondary	Disease-free survival	time from date of operation to date of recurrence of disease, a new occurrence of secondary colorectal cancer, a new occurrence of other malignancy, or deaths from any cause.	3 years after surgery
Secondary	overall survival	time from date of operation to date of death due to any cause.	3 years after surgery
Secondary	quality of life	quality of life will be measured with FACT-C	before study treatment, 7 weeks after completion of chemoradiation, and at 4 weeks after surgery